Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does APIXABAN Cause Therapeutic product effect incomplete? 827 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 827 reports of Therapeutic product effect incomplete have been filed in association with APIXABAN (ELIQUIS). This represents 0.5% of all adverse event reports for APIXABAN.

827
Reports of Therapeutic product effect incomplete with APIXABAN
0.5%
of all APIXABAN reports
54
Deaths
600
Hospitalizations

How Dangerous Is Therapeutic product effect incomplete From APIXABAN?

Of the 827 reports, 54 (6.5%) resulted in death, 600 (72.6%) required hospitalization, and 203 (24.5%) were considered life-threatening.

Is Therapeutic product effect incomplete Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for APIXABAN. However, 827 reports have been filed with the FAERS database.

What Other Side Effects Does APIXABAN Cause?

Death (18,501) Cerebrovascular accident (7,237) Atrial fibrillation (5,690) Off label use (5,590) Thrombosis (5,298) Fall (5,063) Cardiac disorder (4,917) Haemorrhage (4,770) Dyspnoea (4,379) Gastrointestinal haemorrhage (4,030)

What Other Drugs Cause Therapeutic product effect incomplete?

ALBUTEROL (8,496) ADALIMUMAB (6,986) PREDNISONE (6,709) METHOTREXATE (6,037) TOFACITINIB (4,914) SECUKINUMAB (4,661) BUDESONIDE\FORMOTEROL (4,392) TIOTROPIUM (4,327) MEPOLIZUMAB (4,106) ETANERCEPT (3,961)

Which APIXABAN Alternatives Have Lower Therapeutic product effect incomplete Risk?

APIXABAN vs APOMORPHINE APIXABAN vs APRACLONIDINE APIXABAN vs APREMILAST APIXABAN vs APREPITANT APIXABAN vs APROTININ

Related Pages

APIXABAN Full Profile All Therapeutic product effect incomplete Reports All Drugs Causing Therapeutic product effect incomplete APIXABAN Demographics